ASO VISUAL ABSTRACT

ASO Visual Abstract: Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients

Mahsa Taskindoust, BS¹, Samantha M. Thomas, MS^{2,3,4}, Sarah Sammons, MD^{2,5}, Oluwadamilola M. Fayanju, MD, MA, MPHS^{1,2,6,7}, Gayle DiLalla, MD^{1,2}, E. Shelley Hwang, MD, MPH^{1,2}, and Jennifer K. Plichta, MD, MS^{1,2,6}

¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Duke Cancer Institute, Durham, NC;

³Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC; ⁴Department of Biostatistics and Bioinformatics, Duke University, Durham, NC; ⁵Department of Medicine, Duke University Medical Center, Durham, NC; ⁶Department of Population Health Sciences, Duke University Medical Center, Durham, NC; ⁷Department of Surgery, Durham VA Medical Center, Durham, NC

While there is significant heterogeneity, survival outcomes have improved over time for most patients with de novo metastatic breast cancer. For those with limited

distant disease and HER2+ or HR+/HER2- tumors, deaths from noncancer causes are proportionally increasing (<https://doi.org/10.1245/s10434-021-10227-3>).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Podium presentation at the SSO Annual Meeting in March 2021

© Society of Surgical Oncology 2021

Published Online: 13 July 2021

J. K. Plichta, MD, MS
e-mail: jennifer.plichta@duke.edu